Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PET Alzheimer’s coverage query renewed

This article was originally published in The Gray Sheet

Executive Summary

CMS accepts UCLA's revised request for a national coverage decision after the agency issued a non-coverage determination in April (1"The Gray Sheet" April 21, 2003, p. 4). UCLA now is seeking Medicare coverage of PET scans in patients "with a gradually progressive decline in one or more cognitive domains" and/or "cognitive impairment due to memory loss, who have had a comprehensive physical including neurological testing and who do not suffer from severe dementia." CMS expects to complete the review by Jan. 7...

You may also be interested in...



CMS Says No To PET For Alzheimer’s, But Leaves Door Open For Future Studies

CMS continues to support research on FDG-PET in the diagnosis of Alzheimer's disease (AD), despite an April 16 non-coverage decision

Manufacturers Want Delay In Conducting US Nitrosamine Risk Assessments

Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.

Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel